Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Overview of attention for article published in Cardiovascular Diabetology, April 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter: 29 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 44 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 30 X posts from 29 X users, with an upper bound of 47,351 followers.

The cumulative evidence supports the benefits of GLP1Ra💉➕️💊iSGLT on metabolic-cardiovascular-renal disease in 👥️DM2👇👇 Metabolic efects: ⬇️HbA1c ⬇️BW ⬇️SBP Additive efect👉BW/PAS⚠️🚫HbA1c https://t.co/Em3UJXdXRg @PabloCimbaro @EduardoPerna1 @LauraPomares7 htt

08 Apr 2023

Reply Repost Favourite

RT @cristinatejerap: Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is)…

07 Apr 2023

Reply Repost Favourite

RT @cristinatejerap: Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is)…

05 Apr 2023

Reply Repost Favourite

RT @cristinatejerap: Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is)…

04 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 26 additional X posts.